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Tecoma stans is a plant traditionally used in Mexico for the control of diabetes. Amongst the alkaloids isolated from the plant
harvested in Egypt, Tecomine was shown to be one of the compounds responsible for the hypoglycemic action. Given the interest in
substances able to treat type II diabetes, we isolated the main alkaloids present in the plant growing in Egypt and Brazil and tested
them in vivo on db/db mice. Contrary to previous literature reports on different animal models, Tecomine was unable to modify
glycemia; the only effect seen being a decrease in plasma cholesterol levels. On the contrary, when tested in vitro on glucose uptake
in white adipocytes, the compound showed a marked effect. The two other alkaloids isolated, namely 5b-Hydroxyskitanthine, early
called Base C, and Boschniakine were inactive both in vivo and in vitro assays.
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Tecoma stans , a bush common to Latin America, is a
plant traditionally used in Mexico for the control of
diabetes. According to these folk reports, it has been
shown recently that the plant extract is able to reduce
the area under glucose tolerance curve in normal rabbits
[1]. Moreover, intravenous administration of Tecoma
stans leaves infusion in normal dogs was shown to
produce an early hyperglycemic response followed by a
slow decrease of the glucose blood values with a
concomitant hypertriglyceridemia; no important
changes in insuline levels were noted [2]. It is known
that this plant contains monoterpene alkaloids, and two
of these are apparently responsible for the hypoglycae-
mic activity of the plant. In fact, Tecomine 1 and
Tecostanine 2, isolated from Tecoma stans growing in
Egypt, were shown to produce a marked reductions in
the blood sugar of fasting rabbits (normal or alloxan-
treated animals) both orally or i.v.; the mechanism of
action of these substances was not elucidated, but they
showed to be inactive in the absence of pancreas [3,4].
Recently, Tecostanine 2 was shown to be inactive as
hypoglycemic agent in normoglycemic and hyperglyce-
mic rats [5]. Given the great interest in novel agents able
to treat diabetes, we have now investigated the effect on
an in vivo model of genetic diabetes (db/db mouse) of
Tecomine 1 and of the two other alkaloids that are
present in large quantities in both the plants we collected
from Egypt and Brazil, namely 5b-Hydroxyskitanthine
(3), early called Base C, and Boschniakine (4), which at
the best of our knowledge, had never been tested as
antidiabetic agents. A parallel in vitro study on adipo-
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cyte glucose uptake was also performed on compounds
1, 3 and 4.
2. Results and discussion
It is known that Tecoma stans possesses a great
variability in its alkaloidic composition depending on
the place of growth, Tecomine 1 being present in all the
samples examined [6]. We determined the composition
of the alkaloidic fraction of the plant collected in Egypt
and in another country, Brazil, in order to find
substance(s) that could be useful for the treatment of
type II diabetes. The plant collected in Egypt showed a
gas chromatography (GC) of the alkaloidic fraction in
which 3 is 11.37% of the area of the entire chromato-
gram (RT 16.95 min), 4 is 17.30% (RT 18.59 min), 1 is
10.40% (RT 18.93 min), and Tecostanine 2 is 21.88%
(RT 19.13 min) (total 60.90% area of the entire
chromatogram); the plant from Brazil shows for 3
11.77%, for 4 24.89%, for 1 11.48% and Tecostanine 2
is 3.69% (total 51.83% of the entire chromatogram), thus
confirming the variability of the composition of the
alkaloidic fraction of this plant. According to the GC
analysis, we were able to isolate from the crude
alkaloidic fraction in appreciable quantity only com-
pounds 1, 3 and 4 (besides Tecostanine 2 from the plant
collected in Egypt [5]).
All the isolated alkaloids were tested on db/db mice, a
genetic model of type II diabetes characterized by
insulin resistance and obesity. In particular, the Teco-
mine hydrochloride (1a), the 5b-Hydroxyskitanthine
oxalate (3b) and the Boschniakine oxalate hemihydrate
(4a) were administered at the following doses: 1a and 4a
at the dose of 50 mg/kg p.o.; 3b at the dose of 63.4 mg/
kg p.o. Contrary to what previously reported for 1 on
different animal models, none of the compounds proved
able to significantly reduce plasma glycemia or insulin
levels after 2 or 7 h from the treatment. In the same
experimental setting, Rosiglitazone, at the dose of 5 mg/
kg p.o., was able to reduce glycemia (372.69/21.6 mg/dl
versus control 621.09/36.1). However, it should be
noted that compound 1a reduced plasma cholesterol
levels (72.96 mg/dl9/4.08 (SE) versus control (94.489/
3.63 (SE), PB/0.02) while body weight, free fatty acids,
triglycerides and urea, as well as food and water intake
did not change following the treatment.
It is possible that pharmacokinetic factors or a
different sensitivity of the animal species considered
can affect the in vivo activity of 1.
This hypothesis seems to be supported by the results
of a parallel in vitro study which showed that Tecomine
1 exerts a potent stimulating effect on the basal glucose
uptake rate in rat adipocytes from normoglycemic rats,
with an EC50 value of 6.79/10
9 M. On the contrary,
the two other alkaloids tested (3, 4) were inactive up to
100 mM.
More studies are thus needed in order to assess
definitively the therapeutic interest of Tecomine for
the treatment of diabetes.
3. Experimental
3.1. Chemistry
Melting points (m.p.) were determined on a Buchi
melting point apparatus and are uncorrected. Optical
rotation was obtained on a Perkin/Elmer mod. 241
spectropolarimeter. 1H (200 MHz) and 13C (50 MHz)
NMR spectra were recorded on a Bruker AMX-200
spectrophotometer. Chemical shifts are shown in ppm
with TMS as internal standard; J values are given in Hz.
IR spectra were recorded on a Perkin/Elmer FT-IR
spectrophotometer mod. 1600. X-ray crystallography
data were collected on a Enraf/Nonius CAD4 diffract-
ometer. The GC analyses were carried out on a Perkin/
Elmer mod sigma 3b gas chromatograph, equipped with
a flame ionisation detector, connected to a Perkin/
Elmer nelson integrator mod 1022, using a capillary
column (Hewlett-Packard, 25 m/0.31 mm i.d., film
thickness 1.03 mm) cross-linked with 5% phenyl methyl
silicone under the following conditions carrier gas H2,
split ratio 90:10, injector and detector temperature
250 8C and column temperature programmed from
50 8C (5 min) to 200 8C at 10 8C/min. Mass spectra of
eluted peaks were obtained in the above experimental
conditions by means of a mass spectrometer Finnigan
Mat SSQ 710 equipped with a gas chromatograph
Varian 3400 (Centro Interdipartimentale Grandi Stru-
menti, Modena University). Microanalyses were carried
out in the Microanalysis Laboratory of the Diparti-
mento di Scienze Farmaceutiche, Modena University.
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Elemental analyses were within9/0.4% of the theoretical
values. Silica gel (Merck, 70/230 mesh) was used for
column chromatography. Rosiglitazone was synthesized
according to a published procedure [7] (Table 1).
3.2. Plant material
Leaves of Tecoma stans (Juss) (Bignoniaceae) grow-
ing in II Cairo, Egypt, or in Brazil (from San Paulo
province) collected during July 1999 and November
1998, respectively, were used. A voucher specimen
(LC2002/01 and LC2002/02, respectively) was deposited
in the Herbarium of the Dipartimento di Scienze
Farmaceutiche, Universita` di Modena e Reggio Emilia.
3.3. Extraction procedure
The dried leaves (500 g) were extracted (Soxhlet) with
Et2O/NH3 15% (10/90 v/v) (3 l). The organic layer was
then extracted with 4 N HCl (1000 ml); the aqueous
phase was then washed with ether (3/200 ml), basified
with NH3 30% and extracted with CH2Cl2 (2/500 ml).
The organic layer was then dried (Na2SO4) and the
solvent removed under reduced pressure. The crude
alkaloidic fraction thus obtained (3 g from the plants
harvested in Brazil or Egypt) was then chromato-
graphed on silica gel with as mobile phase CH2Cl2 and
increasing quantity of CH3OH (from 0 to 40%). 4 was
eluted at 2% CH3OH (TLC mobile phase CH2Cl2/
CH3OH/NH3 89.5/10/0.5, Rf 0.9), 1 at 5% (TLC, Rf
0.80), 3 at 10% (TLC, Rf 0.29).
3.3.1. Tecomine (1)
Yield 0.2 g, oil; purity (GC) /90%, [a]25D (CHCl3):
/1448 (c/1) ([a ]D (CHCl3) /1608 [8];
1H-NMR
(CDCl3): 1.17 (3H, d, J 6.7), 1.19 (3H, d, J 7.6), 1.78
(2H, t, J 11.1), 1.97 (1H, qd, J 7.6, 3.1), 2.35 (3H, s),
2.50/2.65 (1H, m), 2.70/2.80 (1H, m), 3.05 (1H, ddd, J
11.0, 5.8, 1.5), 3.28 (1H, ddd, J 11.0, 6.0, 2.0), 5.90 (1H,
m), in accordance to Ref. [9]. MS m/z 179 (M, 100),
164 (22), 150 (20), 136 (22), 121 (22), 111 (30), 93 (27), 77
(12), 57 (70), in accordance to Ref. [9].
3.3.2. Tecomine HCl (1a)
M.p. 175/6 8C (CH3OH/Et2O);
1H NMR (DMSO-
d6): 1.11 (3H, d, J 7.40), 1.18 (3H, d, J 6.58), 2.10 (1H,
ddd, J 10.03, 7.31, 2.69), 2.77 (3H, s), 2.78/3.30 (4H,
m), 3.55 (1H, m), 3.80 (1H, m), 6.06 (1H, m), 11.71 (1H
broad s). Anal . C11H17NO /HCl C, H, N.
3.3.3. 5b-Hydroxyskitanthine (3)
Yield 0.4 g, purity (GC) /90%; 1H NMR (CDCl3):
0.92 (3H, d, J 6.83), 1.18 (3H, d, J 6.89), 1.48/1.75 (m,
7H), 1.90/2.10 (m, 2H), 2.24 (s, 3H), 2.65 (ddd, J 10.2,
4.5, 2.2), 2.79 (1H, ddd, J 11.4, 4.5, 2.3). 13C NMR:
13.1, 23.9, 30.4, 33.1, 36.9, 39.6, 45.6, 55.0, 60.3, 62.2,
83.0. MS m/z 183 (M, 90), 182 (100), 166 (30), 164
(32), 150 (80), 122 (30), 108 (28), 98 (20), 84 (70), 74 (40),
58 (38), 57 (60), 55 (35). IR (Nujol) (cm1): 3400. (the
spectra are in accordance with Ref. [10]). In order to
confirm the structure, 3 was converted in its methiodide
3a and subjected to X-ray crystallography.
3.3.4. 5b-Hydroxyskitanthine methiodide (3a)
5b-Hydroxyskitanthine 3 (0.20 g, 1.10 mmol) was
dissolved in anh. Et2O (5 ml); CH3I was added (0.93 ml,
1.50 mmol) at room temperature (r.t.) under stirring. A
white precipitate appeared immediately; the suspension
was stirred for 3 h, then the precipitate was collected,
washed with Et2O and dried. Yield 0.22 g (62%), m.p.
293/5 8C (CH3OH);
1H NMR (DMSO-d6): 0.90 (3H, d,
J 6.85), 1.17 (3H, d, J 6.83), 1.35/2.05 (6H, m), 2.43
(1H, m), 2.90 (1H, t), 3.11 (3H, s), 3.12 (3H, s), 3.45 (3H,
m), 4.45 (1H, s). Crystals suitable for X-ray analysis
were grown from a methanolic solution. The crystal
structure is the same as reported [11], with the same cell
parameters.
3.3.5. 5b-Hydroxyskitanthine (COOH)2 (3b)
M.p. 158/60 8C (CH3OH/Et2O);
1H NMR (DMSO-
d6): 0.89 (3H, d, J 6.85), 1.17 (d, 3H, J 6.83), 1.35/2.05
(m, 6H), 2.15 (m, 1H), 2.42/2.60 (m, 4H), 2.67 (s, 3H),
3.23 (m, 2H), 8.40 (2H, broad s). Anal . C13H23NO5: C,
H, N.
3.3.6. Boschniakine (4)
Yield 0.7 g, oil; purity (GC) /96%, [a]25D (CHCl3)
/22.58 (c/1) ([a ]D /218 [8]; IR (Nujol) (cm
1): 1697;
1H NMR (CDCl3): 1.38 (3H, d, J 6.91), 1.60/1.84 (1H,
m), 2.36/2.54 (1H, m), 3.00/3.48 (3H, m), 8.62 (1H, s),
8.83 (1H, s), 10.23 (1H, s), in accordance to Ref. [12];
Table 1
Elemental analyses
Comp. Formula C Calc./found H Calc./found N Calc./found
1a C11H17NO /HCl 61.25/61.58 8.41/8.33 6.49/6.11
3b C11H21NO /(COOH)2 57.13/57.51 8.48/8.33 5.12/5.40
4a C10H11NO /(COOH)2 /0.5 /H2O 55.38/55.33 5.42/5.18 5.38/5.50
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MS m/z 161 (M, 100), 160 (30), 146 (80), 132 (40), 117
(57), 91 (22), 77 (19), 65 (10), 51 (10).
3.3.7. Boschniakine (COOH)2 /0.5 /H2O (4a)
M.p. 113/6 8C (CH3OH/Et2O);
1H NMR (DMSO-
d6): 1.31 (3H, d, J 6.90), 1.55/1.70 (m, 1H), 2.30/2.45
(m, 1H), 3.00/3.15 (1H, m), 3.19 (1H, s), 3.20/3.30 (2H,
m), 8.68 (1H, s), 8.86 (1H, s), 10.21 (1H, s). Anal .
C12H13NO5.0.5 /H2O: C, H, N.
3.4. Pharmacology
3.4.1. Glucose uptake in Wistar rats white adipocytes
3.4.1.1. Animals. Male Wistar rats (180/200 g) were
obtained from Charles-River Italy breeding colonies.
The animals were housed at 239/1 8C with a 12 h light/
dark cycle, light on at 07:00 h and were fed a standard
laboratory diet with water ad libitum. All the experi-
ments were carried out in accordance with the European
Communities Council Directive of 24 November 1986
(86/609/EEC) for experimental animal care.
3.4.1.2. Adipocyte preparation. Adipocytes were pre-
pared according to Rodbell [13]. The epidydymal fat
pads were removed and placed in oxygenated cold
Krebs bicarbonate buffer pH 7.5 of the following
composition (mM): NaHCO3 (25), glucose (11.1),
NaCl (118), KCl (4.7), KH2PO4 (1.2), MgSO4 (0.6).
The tissue was then minced with scissors and digested
for 40/60 min at 37 8C in Krebs buffer containing
collagenase (0.5 mg/ml; type I, Sigma) and 2% free fatty
acid bovine serum albumin (SIGMA). After digestion
the tissue was filtered on a nylon gauze and washed
extensively with warm Krebs buffer. Adipocytes were
then concentrated and counted. An average amount of
300.000/400.000 cells/tube were used.
3.4.1.3. Glucose uptake. Glucose uptake was measured
in floating, viable, adipocytes using the non metaboli-
sable analogue of glucose, the 3H-2-deoxy-D-glucose
(100 mM, 0.2 mCi/ml).
Cells were first pre-incubated for 10 min at 37 8C in
atmosphere of 5% CO2 before the addition of the
pharmacological stimuli. Insulin (10 nM, Sigma) or
the tested compounds were then added to cell suspen-
sions and incubated for 45 or 10 min, respectively before
the addition of the labelled compound.
Glucose uptake was evaluated after 10 min from the
addition of the 3H-2-deoxy-D-glucose (100 mM, 0.2 mCi/
ml). At that time Phloretin (200 mM; Sigma) was added
to each tube. Cells were then filtered on nitrocellulose
filter (8 mM; Sartorius) under light vacuum. After three
washings with cold Krebs buffer, the filters were dried
up at r.t. and placed in a vials containing Filter-Count
(Packard). The radioactivity was measured using a b-
counter. Basal uptake was completely abolished by the
use of Phloretin (200 mM), whereas the insulin-depen-
dent uptake was inhibited by more than 80% by using
Cytocalasin (20 mM).
Results are expressed as nmoles of deoxy-glucose/106
cells or as the ratio between the uptake measured in
stimulated cells over that measured in cells without any
treatment (basal uptake).
Stock solutions (1 mM) of the compounds 1, 3 and 4
(as free bases) were prepared in DMSO. At the
concentrations used, DMSO (maximum tested 0.01%)
had no effect on glucose uptake. Results are the mean9/
SE of four different exp. run in duplicate. Basal uptake:
1.279/0.22 nmol/106 cells/10 min.
3.4.2. In vivo antidiabetic assays
Male C57BL/KsJ db/db mouse (8 weeks old) were
used. Six animals were used for control and for the
compounds to be assayed. Mouse were treated p.o. twice
each day (at 08:30 and 18:30 h) for 7 days by gavage at
the dose of 50 mg/kg in C.M.C. (1%) and Tween 80
(0.5%) (10 ml/kg) for 1a and 4a; 63.4 mg/kg were used
for 3b; Rosiglitazone was used as a reference compound
at the dose of 5 mg/kg (10 ml/kg), p.o.; then they were
sacrificed at 7th day after 7 h from the last treatment
and the following parameters were determined: plasma
glucose (evaluated by Kit glucose GDH, Roche),
triglycerides, cholesterol and urea (by Kits Roche),
free fatty acids (by Kit NEFA C, Wako). Plasma insulin
was assessed by Kit 125I-Rat insulin (Amersham).
Controls received only vehicle (10 ml/kg).
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